Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaped Marijuana to Reduce Naloxone-Precipitated Withdrawal
NCT05114460Phase 2Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Nov 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cannabis in opioid withdrawal (6 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Clinical Opiate Withdrawal Scale at 4 weeks. Started Nov 2021; status: terminated.
02
Drugs
cannabis
03
Conditions
opioid withdrawal
Beyond the preview
Go deeper on NCT05114460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114460.